MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Verreck, Frank A W ^a   Vervenne, Richard A W ^a   Kondova, Ivanela ^a   van Kralingen, Klaas W ^b   Remarque, Edmond J ^a   Braskamp, Gerco ^a   van der Werff, Nicole M ^a   Kersbergen, Ariena ^a   Ottenhoff, Tom H M ^b   Heidt, Peter J ^a   Gilbert, Sarah C ^c   Gicquel, Brigitte ^d   Hill, Adrian V S ^c   Martin, Carlos ^e   McShane, Helen ^c   Thomas, Alan W ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d INSTITUT PASTEUR   (France)

^e UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; PHOP PROTEIN; VACCINIA VACCINE; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BIOLOGICAL MARKER; DNA VACCINE; LIVE VACCINE; PHOP PROTEIN, BACTERIA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL IMMUNITY; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG TOLERABILITY; GENE DISRUPTION; IMMUNOGENICITY; LUNG TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTECTION; RHESUS MONKEY; SINGLE DRUG DOSE; ANIMAL; BACTERIAL COUNT; BLOOD; GENETICS; IMMUNOLOGY; INFLAMMATION; LUNG; LYMPHOCYTE; MACACA; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PATHOLOGY; RADIOGRAPHY; SECRETION; TREATMENT OUTCOME; TUBERCULOSIS; VACCINIA VIRUS;

BACTERIA (MICROORGANISMS); MACACA MULATTA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; VACCINIA VIRUS ANKARA;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; BIOLOGICAL MARKERS; COLONY COUNT, MICROBIAL; INFLAMMATION; INTERFERON-GAMMA; LUNG; LYMPHOCYTES; MACACA MULATTA; MALE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINIA VIRUS;

EID: 65349186494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005264     Document Type: Article

References (33)

1. Global tuberculosis control: surveillance, planning, financing: WHO report 208. WHO/HTM/TB/2008.393, at http://www.who.int/tb/publications/ 2008/en/index.html.
2. Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345.
3. Skeiky YAW, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469-476.
4. Baumann S, Nasser Eddine A, Kaufmann SH (2006) Progress in tuberculosis vaccine development. Curr Opin Immunol 18: 438-448.
5. Hussey G, Hawkridge T, Hanekom W (2007) Childhood tuberculosis: old and new vaccines. Paediatr Respir Rev 8: 148-154.
6. McShane H, Brookes R, Gilbert SC, Hill AVS (2001) Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 69: 681-686.
7. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.
8. Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, et al. (2005) Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis 85: 29-38.
9. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85a boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
10. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, et al. (2005) Boosting BCG with MVA85a: the first candidate subunit vaccine for tuberculosis clinical trials. Tuberculosis 85: 47-52.
11. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, et al. (2006) Early clinical trials with a new tuberculosis vaccine, MVA85a, in tuberculosis-endemic countries: issues in study design. Lancet Infect Dis 6: 522-528.
12. Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, et al. (2007) Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS ONE 2: e1052.
13. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
14. Pérez E, Samper S, Bordas Y, Guilhot C, Gicquel B, et al. (2001) An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 41: 179-187.
15. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, et al. (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24: 3408-3419.
16. Aguilar D, Infante E, Martin C, Gormley E, Gicquel B, et al. (2007) Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol 147: 330-338.
17. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, et al. (1996) The Philippine cynomolgus monkey (Macaca fascicularis) provides new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 2: 430-436.
18. Langermans JA, Andersen P, van Soolingen D, Vervenne RAW, Frost PA, et al. (2001) Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 98: 11497-11502.
19. Flynn JL, Capuano SV, Croix D, Pawar S, Myers A, et al. (2003) Non-human primates: a model for tuberculosis research. Tuberculosis 83: 116-118.
20. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, et al. (2003) Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the varous manifestations of human M. tuberculosis infection. Infect Immun 71: 5831-5844.
21. McMurray DN (2000) A nonhuman primate model for preclinical testing of new tuberculosis vaccines. Clin Infect Dis 30: S210-212.
22. Langermans JA, Doherty TM, Vervenne RAW, van der Laan T, Lyashchenko K, et al. (2005) Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
23. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, et al. (2005) Novel recombinant BCG and DNA-vaccination against tuberculosis in cynomolgus monkey model. Vaccine 23: 2132-2135.
24. Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T (2007) Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis 87: 518-525.
25. Friqui W, Bottai D, Majlessi L, Monot M, Josselin E, et al. (2008) Control of M.tuberculosis ESAT-6 secretion and specific T cell recognition by phoP. PLoS Pathog 4: e33.
26. Gonzalo Asensio J, Maia C, Ferrer NL, Barilone N, Laval F, et al. (2006) The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem 281: 1313-1316.
27. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Friqui W, et al. (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 104: 5596-5601.
28. Gonzalo-Asensio J, Mostowy S, Harders-Westerveen J, Huygen K, Hernandez-Pando R, et al. (2008) PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS ONE 3: e3496.
29. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, et al. (2005) New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23: 3753-3761.
30. Asensio JA, Arbués A, Pérez E, Gicquel B, Martin C (2008) Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials. Expert Opin Biol Ther 8: 201-211.
31. Gibbs RA, Rogers J, Katze MG, Bumgarner R, Weinstock GM, et al. (2007) Evolutionary and biomedical insights from the rhesus macaque genome. Science 316: 222-234.
32. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
33. Mlika-Cabanne N, Brauner M, Mugusi F, Grenier P, Daley C, et al. (1995) Radographic abnormalities in tuberculosis and risk of coexisting human immunodeficiency virus infection. Methods and preliminary results from Bujumburra, Burundi. Am J Respir Crit Care Med 152: 786-793.